Lifileucel, an autologous tumor-infiltrating lymphocyte (TIL) therapy, is used primarily for the treatment of metastatic melanoma. As a specialized form of immunotherapy, Lifileucel has specific contraindications and considerations for patient selection. Here are key contraindications and considerations:
Contraindications
Severe Allergies or Hypersensitivity:
Patients with known hypersensitivity to any component of Lifileucel or its preparation process should avoid this treatment.
Active Infections:
Patients with active, uncontrolled infections, including systemic infections or sepsis, are typically contraindicated as the treatment can exacerbate these conditions.
Severe Autoimmune Diseases:
Patients with active or severe autoimmune diseases may not be suitable for Lifileucel therapy, as enhancing the immune response could potentially worsen their condition.
Severe Cardiac or Pulmonary Conditions:
Patients with severe or unstable cardiac or pulmonary conditions may be at higher risk for complications during the treatment process